Ronnie Shapira-Frommer, MD, on the Rationale for the KEYNOTE-158 Trial in Patients With Vulvar Squamous Cell Carcinoma

Video

CancerNetwork® spoke with Ronnie Shapira-Frommer, MD, during the Society of Gynecological Oncology 2021 Virtual Annual Meeting on Women’s Cancer about data focusing on a cohort of patients with vulvar cancer treated with pembrolizumab monotherapy.

CancerNetwork® sat down with Ronnie Shapira-Frommer, MD, to discuss the rationale for the phase 2 KEYNOTE-158 trial (NCT02628067), which examined pembrolizumab (Keytruda) monotherapy in patients with advanced solid tumors.

At the Society of Gynecological Oncology (SGO) 2021 Virtual Annual Meeting on Women’s Cancer, Shapira-Frommer presented data on a cohort of patients with vulvar cancer treated on the trial. Results showed that patients with previously treated vulvar squamous cell carcinoma who received single-agent pembrolizumab experienced durable responses across PD-L1 expression levels.

Transcription:

The KEYNOTE-158 study was a multicohort, phase 2 study in [multiple tumor types], and vulvar cancer is one of them. Endometrial cancer, cervical cancer, mesothelioma, and other cohorts were included in the study. Vulvar cancer is a rare cancer, it’s very difficult to enroll patients. Usually, they are elderly patients with multiple diseases [aside from cancer]. It’s also quite hard to evaluate disease since it’s pelvic disease [with] local spreading of disease.

Vulvar cancer was one of the cohorts of the study, and it’s also important to know that vulvar cancer, in most cases, is related to HPV [human papillomavirus] infection. As we know in cervical cancer, the role of pembrolizumab was proven in another cohort of the KEYNOTE-158 study, and it was this study led to the approval by the FDA for this cohort of patients with cervical cancer [that is] PD-L1 positive. Therefore, vulvar cancer was included as well.

References

Frommer RS, Mileshkin L, Manzyuk L, et al. Pembrolizumab for Vulvar Squamous Cell Carcinoma: Results From the Phase 2 KEYNOTE-158 Study. Abstract presented at: Society of Gynecological Oncology 2021 Virtual Annual Meeting on Women’s Cancer; March 19-21, 2021; Virtual. Abstract 11603.

Recent Videos
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight the many advantages to attending the 42nd Annual Miami Breast Cancer Conference, with some additional tidbits to round out the main event.
Other ongoing urothelial cancer trials are assessing enfortumab vedotin–based combinations in the neoadjuvant setting.
Given resource scarcity, developing practice strategies for resource-constrained settings would require aid from commercial and government stakeholders.
Approximately 95% of those with a complete response to enfortumab vedotin plus pembrolizumab were alive after 2 years in the phase 3 EV-302 trial.
Thomas Powles, MBBS, MRCP, MD, highlighted fatigue, nausea, and peripheral neuropathy as toxicities observed with enfortumab vedotin plus pembrolizumab.
Large international meetings may facilitate conversations regarding disparities of care outside of high-income countries.
Related Content